The establishment of a new bio bank at Glostrup Hospital, will drive the expansion of individually tailored treatment courses for rheumatoid arthritis patients. The hope is to be able to offer regimens based on more effective biologic response modifiers, the so-called biologics.
The Danish regions, who are responsible for direct healthcare, spend approx. €133 million ($149 million) annually on biologics, amounting to 15 pct. of the total medicine expenses at hospitals; but for a third of arthritis patients, the effect of a biologics based regimen is either lacking or insufficient.
The new bio bank is charged with analyzinh blood and tissue samples for bio markers and genetic changes, cursors which will then be used to make more accurate diagnoses and predict disease development. Based on more detailed pathological pictures of the individual patient, doctors are able to prescribe the most beneficial medication for each individual arthritis patient.
The new bio bank has been granted €1,8 million ($2 million) by Danish Regions and €460.000 ($521.000) by Gigtforeningen.